A.P. Pharma granisetron formulation delay
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Redwood City, Calif.-based A.P. Pharma expects to submit an NDA for its novel formulation of the antiemetic granisetron (Roche's Kytril and generics) by the end of 2007. The firm had expected initial Phase III data in Q1 2007, but is revising that timing to the second half of next year "due to a slower-than-expected start in getting IRB approvals and clinical sites prepared to begin enrolling patients, and in recruiting patients during the summer months." The firm's formulation of the established 5-HT3 antagonist employs a proprietary Biochronomer bioerodible drug delivery system...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.